scholarly journals Increased Risk of Infection and Mortality in Women after Cardiac Surgery Related to Allogeneic Blood Transfusion

2007 ◽  
Vol 16 (10) ◽  
pp. 1412-1420 ◽  
Author(s):  
Mary A.M. Rogers ◽  
Neil Blumberg ◽  
Joanna M. Heal ◽  
George L. Hicks, Jr.
Blood ◽  
2009 ◽  
Vol 113 (15) ◽  
pp. 3406-3417 ◽  
Author(s):  
Eleftherios C. Vamvakas ◽  
Morris A. Blajchman

Abstract As the risks of allogeneic blood transfusion (ABT)–transmitted viruses were reduced to exceedingly low levels in the US, transfusion-related acute lung injury (TRALI), hemolytic transfusion reactions (HTRs), and transfusion-associated sepsis (TAS) emerged as the leading causes of ABT-related deaths. Since 2004, preventive measures for TRALI and TAS have been implemented, but their implementation remains incomplete. Infectious causes of ABT-related deaths currently account for less than 15% of all transfusion-related mortality, but the possibility remains that a new transfusion-transmitted agent causing a fatal infectious disease may emerge in the future. Aside from these established complications of ABT, randomized controlled trials comparing recipients of non–white blood cell (WBC)–reduced versus WBC-reduced blood components in cardiac surgery have documented increased mortality in association with the use of non-WBC–reduced ABT. ABT-related mortality can thus be further reduced by universally applying the policies of avoiding prospective donors alloimmunized to WBC antigens from donating plasma products, adopting strategies to prevent HTRs, WBC-reducing components transfused to patients undergoing cardiac surgery, reducing exposure to allogeneic donors through conservative transfusion guidelines and avoidance of product pooling, and implementing pathogen-reduction technologies to address the residual risk of TAS as well as the potential risk of the next transfusion-transmitted agent to emerge in the foreseeable future.


2006 ◽  
Vol 34 (4) ◽  
pp. 433-454 ◽  
Author(s):  
Raul C. Verdin-Vasquez ◽  
Carlos Zepeda-Perez ◽  
Rolando Ferra-Ferrer ◽  
Adolfo Chavez-Negrete ◽  
Francisco Contreras ◽  
...  

2018 ◽  
Vol 8 (2) ◽  
pp. 198-207 ◽  
Author(s):  
Christian Fisahn ◽  
Cameron Schmidt ◽  
Josh E. Schroeder ◽  
Emiliano Vialle ◽  
Isador H. Lieberman ◽  
...  

Study Design: Systematic review. Objectives: Allogeneic blood transfusion-related immunomodulation may relatively suppress the immune system, heightening the risk of infection following spine surgery. This systematic review seeks to determine whether allogeneic blood transfusion increases the risk of postoperative infection and whether there are any factors that modify this association. Methods: PubMed, Cochrane Central Register of Controlled Trials, and reference lists from included studies were searched from inception to April 20, 2017 to identify studies examining the risk of infection following allogeneic blood transfusion in adult patients receiving surgery for degenerative spine disease. Results: Eleven retrospective cohort or case-control studies, involving 8428 transfusion patients and 43 242 nontransfusion patients, were identified as meeting the inclusion criteria. Regarding surgical site infection (SSI), the results were mixed with roughly half reporting a significant association. There was an association between allogeneic transfusion and urinary tract infection (UTI) and any infection, but not respiratory tract infection. There was no statistical modifying effect of lumbar versus thoracic surgery on the association of allogeneic transfusion and SSI, though subgroup analyses in 3 of 4 studies reported a statistical association between transfusion and postoperative infections, including SSI, UTI, and any infection within the lumbar spine. Conclusions: This systematic review failed to find a consistent association between allogeneic transfusion and postoperative infection in spine surgery patients. However, these studies were all retrospective with a high or moderately high risk of bias. To properly examine this association an observational prospective study of sufficient power, estimated as 2400 patients, is required.


2006 ◽  
Vol 23 (Supplement 38) ◽  
pp. 1-2
Author(s):  
T. Vymazal ◽  
M. Horacek ◽  
R. Durpekt ◽  
M. Hladikova ◽  
K. Cvachovec

Sign in / Sign up

Export Citation Format

Share Document